Pfizer reports positive results from Phase IIb trial of berobenatide

Pfizer has reported Phase IIb results for its investigational monthly GLP-1 RA peptide, berobenatide, to treat obesity and type 2 diabetes. Data demonstrated proof-of-concept for berobenatide as a first-in-class monthly GLP-1 RA peptide with competitive weight loss outcomes. The Phase IIb VESPER-1, VESPER-2, and VESPER-3 studies examined weekly and monthly dosing in adults with obesity, with and without type 2 diabetes. Credit: PanuShot / Shutterstock.com. Pfizer has reported detailed Phase IIb results for its investigational monthly glucagon-like peptide-1 receptor agonist (GLP-1 RA) peptide, berobenatide (PF’3944), in the treatment of obesity and type 2 diabetes (T2D). The studies aimed to identify…

Source: Clinical Trials Arena